| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2006-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008542256-A |
| titleOfInvention |
Novel acetylsalicylic acid formulation |
| abstract |
The present invention relates to acetylsalicylic acid based microcapsule pharmaceutical compositions that selectively inhibit COX in the portal vein and / or liver to reduce thromboxane production. Furthermore, the pharmaceutical composition minimizes COX inhibition in the systemic circulation to optimize the inhibition of platelet aggregation. Certain embodiments also address methods for preventing and / or treating these diseases using these oral compositions that enhance the safety of antithrombotic therapy. Other embodiments contemplate oral pharmaceutical compositions that combine acetylsalicylic acid and an antiplatelet aggregating agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019089833-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016104778-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019142860-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012531430-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012528171-A |
| priorityDate |
2005-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |